Yes. A comprehensive skin consultation is required prior to any laser resurfacing to determine suitability, assess skin integrity, and establish preparation and recovery support. This includes screening for atypical lesions and evaluating factors that may influence pigment response or healing.

Where a lesion or skin change is atypical, evolving, or clinically suspicious, treatment is not performed and referral is made for dermatological assessment prior to any intervention.

Suitability is determined by assessing variables known to influence melanocyte response and wound healing. These may include current or recent medications, topical products, occupational or environmental exposure (including heat, UV, or irritants), immune or inflammatory status, and hormonal influences (including peri- or post-menopausal status).

These variables can significantly affect post-treatment response and pigment behaviour and are assessed during consultation to guide safe treatment planning.

Yes. Full disclosure of medications, supplements, and topical products is essential. Some agents may affect photosensitivity, skin turnover, inflammation, or healing response, and may require a tailored preparation and recovery plan.

For safety reasons, specific medication and product guidance is confirmed during consultation based on your clinical history and planned treatment depth.

Laser resurfacing is often more predictable in lower to mid Fitzpatrick skin types where melanocyte response can be more reliably controlled. Higher Fitzpatrick skin types may still be suitable, however they may require modified planning, extended preparation, and pigment-stabilising support to minimise risk.

Where pigmentary risk is considered elevated, treatment may be modified, deferred, or referred for specialist oversight to ensure appropriate safety standards.

Yes. For patient safety, laser resurfacing is not performed where risk outweighs benefit or where diagnostic clarification is required. This may include clinically suspicious or evolving lesions, known or suspected malignancy, active infection or inflammation at the treatment site, and a history of keloid or significant hypertrophic scarring.

Where suitability is uncertain, referral is made to a dermatologist or appropriate medical practitioner prior to any intervention.

Risk management is individualised. Where clinically indicated, a preparation and recovery protocol may be recommended to support barrier integrity and pigment stability. This may include short-term use of pigment-modulating strategies (such as tyrosinase inhibitors) commenced prior to treatment and continued through recovery, alongside strict photoprotection and guided aftercare.

Specific products and timing are determined clinically during consultation.

Pricing varies depending on the treatment area, indication, and clinical complexity. All pricing reflects comprehensive care, including pre-treatment preparation, post-treatment support, and a prescribed home care kit to support healing, barrier recovery, and outcome optimisation.

Patient safety, recovery quality, and long-term skin health are prioritised. Lower-cost or abbreviated treatments do not equate to better outcomes and may increase the risk of complications where appropriate preparation, aftercare, or clinical oversight is lacking.